# [SCI-Idea] Aging Biology & Longevity Science
⏎
**Aging biology** is the scientific study of the molecular and cellular processes underlying biological aging — and the emerging evidence that aging is not a fixed programme but a set of modifiable processes that can be slowed, halted, or partially reversed.
⏎
## Overview
⏎
The Hallmarks of Aging (López-Otín et al., 2013; updated 2023 to 12 hallmarks) provide the conceptual framework: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation (inflammaging), and dysbiosis. Each hallmark has been intervened upon in animal models with life extension results.
⏎
Key developments:
- **Yamanaka factors (2006)**: Oct4, Sox2, Klf4, c-Myc reprogram somatic cells to pluripotency. Partial reprogramming (cycled, without full dedifferentiation) reverses aging phenotypes in mice (Belmonte lab, Salk Institute) and restores vision in old mice (Sinclair lab, Harvard).
- **Senolytics**: drugs (dasatinib + quercetin, navitoclax) that selectively kill senescent cells extend healthspan and lifespan in mice; human trials ongoing (Unity Biotechnology, Oisín Biotechnologies).
- **Epigenetic reprogramming**: the Horvath clock gives a quantitative biological age; interventions that reverse it in blood are being tested.
- **Caloric restriction mimetics, rapamycin**: extend lifespan in multiple model organisms.
⏎
## Key Research Groups
⏎
Altos Labs (USD 3B raised; Shinya Yamanaka, David Sinclair, Juan Carlos Izpisua Belmonte, Steve Horvath), Calico (Google/Alphabet, USD 700M+), Unity Biotechnology, Genentech (anti-ageing pipeline), Retro Biosciences (Sam Altman, USD 180M).
⏎
## Economic Potential
⏎
Extending healthy human lifespan by 10 years would generate USD 37T in additional economic output and quality-adjusted life years (QALY value, Scott et al., *Nature Aging* 2021). If aging is approved as an FDA disease indication, the pharmaceutical market alone could exceed USD 1T/year. Anti-aging cosmeceutical market already USD 60B/year.
⏎
## Discovery Character
⏎
**Surprise level**: High — aging was considered immutable biology for most of history; its characterisation as a modifiable disease state is a profound conceptual shift.
⏎
**Mode**: Hybrid — systematic epigenetics + serendipitous discovery of Yamanaka factors (originally for cell reprogramming, not anti-aging) + AI-driven drug screening.
⏎
## What This Enables
⏎
- **[TECH-Idea] mRNA & RNA Therapeutics** — mRNA delivery of reprogramming factors or longevity-associated proteins is the leading therapeutic vector for in vivo rejuvenation.
- **[TECH-Idea] CRISPR Gene Therapy** — correcting aging-associated mutations and epigenetic errors requires precise gene editing.
⏎
# Parents
⏎
* [SCI] Molecular Biology & Biochemistry⏎